To identify the aetiology of CA-ARTI in a subset of participants in the WP4 trial, and to perform laboratory validations of the pathogen and host-based CA-ARTI-Dx evaluated in WP4, using samples obtained in the trial.
To provide comprehensive data on the laboratory-based validations (detection of pathogen, host biomarker, and AMR) of the CA-ARTI-Dx being evaluated on a regular basis in order to ‘machine-learn’ the clinical algorithms developed in WP1.
To screen for host biomarkers in an initial subset of blood/serum samples collected in WP4, and then validate these on the subsequent blood/serum samples from WP4.
To understand and quantify the burden of AMR, in a subset of nasal, pharyngeal and gastrointestinal samples, with respect to the type, days and doses of antibiotics prescribed based on the following outcomes: i) development or amplification of the AMR burden in the “normal” respiratory and intestinal flora after completion of antibiotic therapy, and ii) selection of pathogens with a resistant phenotype post therapy. These data will allow estimation of the cost of AMR and will feed into WP5.
To develop and support a biobank of well-characterized samples (including blood/serum and other relevant samples to be defined) and bacterial strains isolated from CA-ARTI patients.
https://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.png00melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-09-29 10:13:222019-11-19 10:16:16WP Co-Lead Face-to-Face & Business Plan Meeting
University of Antwerp, bioMérieux, and Wellcome Trust
to coordinate VALUE-Dx, a European Public-Private Partnership
to fight antimicrobial resistance through diagnostics
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-09-26 14:38:492019-09-30 17:10:40Launch of VALUE-Dx
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.